Biomarkers for Early Detection of Alzheimer Pathology

The increasing prevalence of Alzheimer’s disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T1ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer’s disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

[1]  A. Verma,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .

[2]  J. Trojanowski,et al.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics , 2007, Nature Reviews Drug Discovery.

[3]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[4]  D. Galasko.  Biological markers and the treatment of Alzheimer’s Disease , 2001, Journal of Molecular Neuroscience.

[5]  Harald Hampel,et al.  CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease , 2001, Molecular Neurobiology.

[6]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[7]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[8]  Andrew J Wheaton,et al.  In vivo measurement of plaque burden in a mouse model of Alzheimer's disease , 2006, Journal of magnetic resonance imaging : JMRI.

[9]  J. Trojanowski,et al.  Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late-life dementia , 2006, Alzheimer's & Dementia.

[10]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[11]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[12]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[13]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[14]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[15]  H. Kung,et al.  F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. , 2005, Nuclear medicine and biology.

[16]  S. Leurgans,et al.  MRI predictors of risk of incident Alzheimer disease , 2005, Neurology.

[17]  D. Skovronsky,et al.  Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease , 2004, Brain Research.

[18]  C. DeCarli,et al.  P3-065 FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous , 2004, Neurobiology of Aging.

[19]  C. DeCarli,et al.  P3-070 Adding FDG-PET to clinical history and examination improves the accuracy of dementia diagnosis , 2004, Neurobiology of Aging.

[20]  Arijitt Borthakur,et al.  In vivo measurement of T1ρ dispersion in the human brain at 1.5 tesla , 2004 .

[21]  T. Finucane.  Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. , 2004, Annals of internal medicine.

[22]  K. Blennow.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[23]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[24]  J. Yesavage,et al.  Differential associations between entorhinal and hippocampal volumes and memory performance in older adults. , 2003, Behavioral neuroscience.

[25]  Deformable Registration of Cortical Structures via Hybrid Volumetric and Surface Warping , 2003, MICCAI.

[26]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[27]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[28]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .

[29]  Jean-Claude Baron,et al.  Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging , 2003, NeuroImage.

[30]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[31]  A. Pfefferbaum,et al.  Differential rates of regional brain change in callosal and ventricular size: a 4-year longitudinal MRI study of elderly men. , 2002, Cerebral cortex.

[32]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[33]  D. Bennett,et al.  MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease☆ ☆ This research was supported by grants P01 AG09466 and P30 AG10161 from the National Institute on Aging, National Institutes of Health. , 2001, Neurobiology of Aging.

[34]  R. V. Van Heertum,et al.  SPECT perfusion imaging in the diagnosis of Alzheimer’s disease , 2001, Neurology.

[35]  S. Joshi,et al.  Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus , 2000, Neurology.

[36]  Nobuyuki Okamura,et al.  CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study , 2000, Experimental Neurology.

[37]  S. Resnick,et al.  One-year age changes in MRI brain volumes in older adults. , 2000, Cerebral cortex.

[38]  G A Johnson,et al.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Wiśniewski,et al.  Contribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer's Disease , 1997, International Psychogeriatrics.

[40]  F Barkhof,et al.  Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging , 1997, European Neurology.